| Literature DB >> 35300094 |
Andreas Beuchel1, Dina Robaa1, Dereje A Negatu2,3, Abdeldjalil Madani2, Nadine Alvarez2, Matthew D Zimmerman2, Adrian Richter1, Lea Mann1, Sophie Hoenke4, René Csuk4, Thomas Dick2,5,6, Peter Imming1.
Abstract
Mycobacterium abscessus causes difficult-to-cure pulmonary infections. The bacterium is resistant to most anti-infective agents, including first line antituberculosis (anti-TB) drugs. MMV688844 (844) is a piperidine-4-carboxamide (P4C) with bactericidal properties against M. abscessus. We recently identified DNA gyrase as the molecular target of 844. Here, we present in silico docking and genetic evidence suggesting that P4Cs display a similar binding mode to DNA gyrase as gepotidacin. Gepotidacin is a member of the Novel Bacterial Topoisomerase Inhibitors (NBTIs), a new class of nonfluoroquinolone DNA gyrase poisons. Thus, our work suggests that P4Cs present a novel structural subclass of NBTI. We describe structure-activity relationship studies of 844 leading to analogues showing increased antibacterial activity. Selected derivatives were tested for their inhibitory activity against recombinant M. abscessus DNA gyrase. Further optimization of the lead structures led to improved stability in mouse plasma and increased oral bioavailability.Entities:
Year: 2022 PMID: 35300094 PMCID: PMC8919391 DOI: 10.1021/acsmedchemlett.1c00549
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.345